Darin Christensen, MD
Psychiatry · Fishersville, VANPI 1922093772
Payments from drug & device makers
Across 759 payments — averaging $15.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$2K
- Johnson & Johnson$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$1K
- Supernus Pharmaceuticals, Inc.$942
- Sunovion Pharmaceuticals Inc.$811
- plus $4K from 21 others
What the payments were for
- Food & beverage$11,70599%
- Education$681%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 136 | $1,818 |
| Johnson & Johnson | 62 | $1,577 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 105 | $1,517 |
| AbbVie(2 entities) | 123 | $1,399 |
| Supernus Pharmaceuticals, Inc. | 79 | $942 |
| Sunovion Pharmaceuticals Inc. | 74 | $811 |
| Neuronetics, Inc. | 8 | $506 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $473 |
| Ironshore Pharmaceuticals Inc. | 21 | $452 |
| Vanda Pharmaceuticals Inc. | 21 | $448 |
| Otsuka America Pharmaceutical, Inc. | 20 | $347 |
| Teva Pharmaceuticals USA, Inc. | 15 | $309 |
| Alkermes, Inc. | 17 | $278 |
| Neurocrine Biosciences, Inc. | 9 | $156 |
| Indivior Inc. | 9 | $130 |
| Axsome Therapeutics, Inc. | 6 | $117 |
| Eisai Inc. | 5 | $87 |
| Shire North American Group Inc | 5 | $86 |
| Corium, LLC | 4 | $64 |
| E.r. Squibb & Sons, L.L.C. | 3 | $56 |
| Almatica Pharma LLC | 2 | $49 |
| Adlon Therapeutics L.p. | 3 | $47 |
| Noven Therapeutics, LLC | 2 | $32 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
| Vertical Pharmaceuticals, LLC | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,773 in reported general payments places this provider in the 90th percentile of 884 psychiatry providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $102,088 |
| SpravatoEsketamine Hcl | 43 | $63,688 |
| Abilify MaintenaAripiprazole | 22 | $61,697 |
| VraylarCariprazine Hcl | 23 | $43,684 |
| RexultiBrexpiprazole | 19 | $28,201 |
| FetzimaLevomilnacipran Hcl | 42 | $24,311 |
| TrintellixVortioxetine Hydrobromide | 32 | $18,218 |
| AuvelityDextromethorphan Hbr/Bupropion | 14 | $14,296 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 54 | $12,320 |
| VyvanseLisdexamfetamine Dimesylate | 28 | $10,791 |
| Aripiprazole | 192 | $9,251 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 373 | $5,802 |
| Lisdexamfetamine Dimesylate | 25 | $5,437 |
| Quetiapine Fumarate | 254 | $5,214 |
| Triazolam | 30 | $4,865 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $156 | $102,08812 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $347 | $89,89841 claims |
| AbbVieVraylar, Fetzima | $1,399 | $67,99465 claims |
| Johnson & JohnsonSpravato | $1,577 | $63,68843 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $473 | $29,00960 claims |
| Axsome Therapeutics, Inc.Auvelity | $117 | $14,29614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 884 psychiatry providers in Virginia.
Other psychiatry in Fishersville
- Niku SinghFalls Church$2.5M
- David ScheidererRoanoke$2.4M
- Kent McDanielGlen Allen$2.1M
- Jasdeep MiglaniManassas$958K
- Frederick MoellerRichmond$678K
- David SpiegelNorfolk$565K
- Christopher van EyckStafford$392K
- Anita ClaytonCharlottesville$356K
- Anita KablingerRoanoke$333K
- William YetterVirginia Beach$312K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.